Canada markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.33+0.96 (+1.80%)
At close: 04:02PM EST
54.62 +0.29 (+0.53%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close53.37
Bid54.51 x 1400
Ask54.60 x 2200
Day's Range53.10 - 54.67
52 Week Range33.36 - 61.71
Avg. Volume45,653,990
Market Cap304.947B
Beta (5Y Monthly)0.64
PE Ratio (TTM)15.52
Earnings DateN/A
Forward Dividend & Yield1.60 (2.94%)
Ex-Dividend DateJan. 27, 2022
1y Target EstN/A
  • Business Wire

    European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer

    NEW YORK, January 28, 2022--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

  • Business Wire

    Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment

    NEW YORK, January 27, 2022--Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer’s PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

  • Business Wire

    Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

    NEW YORK & MAINZ, Germany, January 25, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine. The study will draw upon some participants from the companies’ Phase